Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-12-13
2005-12-13
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S241000, C514S256000, C514S291000, C514S292000, C514S293000, C514S307000, C514S311000, C544S180000, C544S333000, C546S081000, C546S082000, C546S084000, C546S139000, C546S152000, C540S577000
Reexamination Certificate
active
06974824
ABSTRACT:
Kappa opioid receptor antagonists are provided that yield significant improvements in functional binding assays to kappa opioid receptors relative to nor-BNI, and the use of these antagonists in treatment of disease states that are ameliorated by binding of the kappa opioid receptor such as heroin or cocaine addictions.
REFERENCES:
patent: 5767131 (1998-06-01), Gluchowski et al.
patent: 6159990 (2000-12-01), Lagu et al.
patent: 6218390 (2001-04-01), Lagu et al.
patent: 6268369 (2001-07-01), Nagarathnam et al.
patent: 2002/0013321 (2002-01-01), Liras
patent: 2004/0072865 (2004-04-01), Bouillot et al.
patent: 1 038 872 (2000-09-01), None
Carroll F. Ivy
Mascarella S. Wayne
Thomas James B.
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
Research Triangle Institute
Truong Tamthom N.
Wilson James O.
LandOfFree
Kappa opioid receptor ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Kappa opioid receptor ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Kappa opioid receptor ligands will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3468755